Hikvision launches groundbreaking "AcuSeek NVR": Redefining video retrieval with large multimodal AI models
Large multimodal AI models enable the "Search by Text" era
The AcuSeek NVR leverages Hikvision's proprietary Guanlan large-scale AI model technology, utilizing massive parameter training and sample datasets to establish cross-modal text-image comprehension capabilities. Users can simply input a single phrase or keyword such as "person on a phone call," "white van," or "person walking a dog," and the system rapidly extracts subject features from video footage while aligning them semantically to achieve efficient retrieval.
Four core advantages defining industry standards
Search Broadly: The system covers high-frequency security subjects including people, motor vehicles, and non-motor vehicles, while supporting open semantic searches for specific items such as wheeled suitcases and small carts, as well as anomalies like not wearing helmets when required, meeting diverse scenario requirements.
Search Accurately: Through feature alignment technology, the system precisely interprets complex descriptions such as "person wearing a hat and black clothing" or "child carrying a backpack," significantly lowering false detection rates.
Search Instantly: The system responds in seconds, rapidly locating subjects from extensive video footage and enhancing emergency response efficiency.
Search Flexibly: The system user interface provides convenient shortcuts including "Find People," "Find Vehicles," and "Find Pets," while supporting user-customizable search phrases with an extremely low operational threshold that requires no professional training.
Unlocking intelligent value, from security to everyday life
The AcuSeek NVR can be widely applied across physical security, traffic management, and community service sectors. Examples include:
Physical Security: Rapidly screening object characteristics such as "black SUV with round headlights" to assist investigations.
Traffic Management: Searching for "scooters" and "motorcycles" that have entered restricted road sections to enhance enforcement efficiency.
Community Service: Helping residents locate lost pets or missing items, enhancing community service capabilities.
Leo Chen, the product manager at Hikvision, stated: "The launch of the AcuSeek NVR addresses the pain points of traditional video retrieval that relies on manual annotation and suffers from low efficiency. Moving forward, we will continue optimizing AI model algorithms, expanding into more vertical scenarios, and promoting the deep integration of AI technology with security applications."
Pre-orders for the AcuSeek NVR are now available worldwide. For additional information, please visit the Hikvision official website or contact your local distributor.
View original content to download multimedia:https://www.prnewswire.com/news-releases/hikvision-launches-groundbreaking-acuseek-nvr-redefining-video-retrieval-with-large-multimodal-ai-models-302477358.html
SOURCE Hikvision Digital Technology
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/10/c7491.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Google packs new Pixel phones with AI
Google on Wednesday unveiled new Pixel 10 smartphones, showcasing artificial intelligence (AI) capabilities woven into its Android mobile operating system. The line-up of new products included a foldable phone, improved Pixel smartwatch, and ear buds all synced to work with AI and each other. "Pixel continues to be the best way for people to try out the latest bleeding-edge AI from Google," product manager Tyler Kugler said during a briefing with journalists. Pixel phones claim a scant portion of a high-end smartphone market ruled by Apple, Samsung and Xiaomi, but custom Google hardware is an opportunity for the internet giant to highlight what is possible with its Android mobile operating system. And while Samsung routinely ranks as the world's top smartphone seller, it powers handsets with Android software from Google. "Initially, Google Pixel devices were designed as a technological showcase to limit Android fragmentation and accelerate innovation," said Forrester principal analyst Thomas Husson. "Ten years later, the strategic challenge is still not to become the market leader, but to demonstrate the value of Google's integrated ecosystem." The tactic promises to promote use of Google's platform by handset makers and is a spin on the way Apple ties together its iPhones and other devices with its software. Meanwhile, with Apple seen as lagging in the fierce AI race, Google has touted all-out efforts to integrate advanced AI throughout its offerings as it competes with powerhouses such as Amazon, Meta, and Microsoft. "Its positioning remains premium and its market share is less than 5 percent, but in the age of AI, it is a true laboratory of innovation," Husson said of the Pixel smartphone line. It is also "a means of countering Apple's integrated hardware-software-services strategy while remaining a strategic partner for Samsung and the Android ecosystem," Husson added. AI built into new Pixel phones lets Gemini AI assistant look through the cameras to "see" what users see, answering questions or providing tips about locations, objects or situations, according to Kugler. Google is not the only one putting AI in phones. South Korean consumer electronics giant Samsung has made AI a centerpiece of its Galaxy smartphone line and recently released a new Galaxy Z Fold7. Google's product team described the new Pixel Watch 4 as a redesigned experience that marks the biggest update to the line. Features include smartwatch fitness tracking fine-tuned to distinguish between activities such as walking, bicycling, or tennis. The Pixel Watch also enables users to command Gemini AI assistant from one's wrist. Gemini detects the mood of whoever is speaking to it and adjusts its responses accordingly, and can even "look" through the phone camera to offer photo suggestions, according to the Google team. gc-juj/ksb Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Brokers risk falling behind as AI disruption accelerates
The majority of UK SMEs are comfortable with AI assessing their insurance needs and recommending the most suitable coverage options, according to GlobalData surveying. Meanwhile, AI-native insurance broker Meshed has secured backing from Aviva and other investors, with the aim of reshaping the commercial insurance market for SMEs. GlobalData's 2025 UK SME Insurance Survey has found that 64.5% of SMEs are comfortable, to some extent, with AI assessing their insurance needs and recommending the most suitable coverage options. Moreover, over a quarter of SMEs (26.7%) cited that they were extremely comfortable with this. How comfortable are you/would you be for an AI tool to do the following? 2025 Meanwhile, Meshed has raised £950,000 ($1.3m) in an oversubscribed pre-seed funding round to transform the commercial insurance market for SMEs. Investors included Haatch, Aviva via Founders Factory, the Exponential Science Foundation, and several angel backers. Meshed highlights that around 80% of UK SMEs remain underinsured, largely due to outdated brokerage practices and inefficient manual processes. By deploying AI-powered agents for quoting, data collection, and other routine tasks, the firm aims to cut administrative costs, reduce premiums, and enable brokers to focus more on client relationships and specialist advice. Yet, findings from our 2025 UK Commercial Insurance Broker Survey indicate that brokers may be underestimating the scale of disruption that AI could bring. Only 5.2% of brokers see AI as the biggest threat to their business, compared with 13.2% citing competition from other brokers and 11.2% from direct players. Moreover, adoption remains limited, with just 5.9% of brokers using AI-driven policy recommendation tools, while 78.6% report no plans to adopt them. Brokers should recognize that while AI may not seem like the greatest threat today, failing to adopt it could make it one tomorrow. By overlooking AI, brokers risk falling behind faster-moving competitors and losing relevance in a market where efficiency and digital capabilities increasingly drive client expectations. "Brokers risk falling behind as AI disruption accelerates" was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
